Foamix Pharmaceuticals Company Profile (NASDAQ:FOMX)

About Foamix Pharmaceuticals

Foamix Pharmaceuticals logoFoamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations. The Company develops FMX101, FMX102, FMX103 and FDX104 using its technology, which includes foam-based platforms. The Company's lead product candidate FMX101, is a novel topical foam formulation of the antibiotic minocycline. The Company develops FMX102, a minocycline foam product candidate for the treatment of impetigo, including cases of impetigo caused by methicillin-resistant staphylococcus aureus (MRSA). It is also developing FMX103, minocycline foam for rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It completed a Phase II clinical trial for FMX102.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FOMX
  • CUSIP:
Key Metrics:
  • Previous Close: $10.24
  • 50 Day Moving Average: $10.41
  • 200 Day Moving Average: $9.50
  • 52-Week Range: $5.48 - $11.27
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.97
  • P/E Growth: 0.00
  • Market Cap: $374.77M
  • Outstanding Shares: 36,599,000
  • Beta: 1.62
Profitability:
  • Net Margins: -554.14%
  • Return on Equity: -22.55%
  • Return on Assets: -21.59%
Debt:
  • Current Ratio: 18.90%
  • Quick Ratio: 18.90%
Additional Links:
Companies Related to Foamix Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Foamix Pharmaceuticals (NASDAQ:FOMX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (105.08% upside)

Analysts' Ratings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017Credit Suisse GroupInitiated CoverageOutperform$22.00View Rating Details
8/13/2016GuggenheimReiterated RatingBuy$10.00 -> $20.00View Rating Details
3/16/2015Barclays PLCBoost Price TargetOverweight$11.00 -> $15.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2017Q416($0.29)N/AView Earnings Details
8/10/2016Q216($0.25)($0.27)$1.10 million$1.50 millionViewListenView Earnings Details
5/10/2016Q1($0.23)($0.15)ViewListenView Earnings Details
11/11/2015Q315($0.20)($0.11)ViewListenView Earnings Details
8/19/2015Q215($0.14)($0.18)ViewListenView Earnings Details
5/12/2015Q1($0.12)($0.14)ViewN/AView Earnings Details
4/15/2015($0.12)($0.18)ViewN/AView Earnings Details
3/18/2015($0.05)($0.01)ViewN/AView Earnings Details
11/14/2014Q314($0.07)($0.61)$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Foamix Pharmaceuticals (NASDAQ:FOMX)
Current Year EPS Consensus Estimate: $-0.84 EPS
Next Year EPS Consensus Estimate: $-1.47 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.22)($0.22)($0.22)
Q3 20161($0.20)($0.20)($0.20)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Foamix Pharmaceuticals (NASDAQ:FOMX)
DateHeadline
finance.yahoo.com logoCoverage initiated on Foamix by Credit Suisse (NASDAQ:FOMX)
finance.yahoo.com - February 16 at 5:14 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22 (NASDAQ:FOMX)
finance.yahoo.com - February 7 at 6:30 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference (NASDAQ:FOMX)
finance.yahoo.com - February 6 at 11:19 AM
capitalcube.com logoFoamix Pharmaceuticals Ltd. – Value Analysis (NASDAQ:FOMX) : January 27, 2017 (NASDAQ:FOMX)
www.capitalcube.com - January 27 at 7:03 PM
capitalcube.com logoFoamix Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : FOMX-US : January 26, 2017 (NASDAQ:FOMX)
www.capitalcube.com - January 26 at 3:20 PM
News IconFoamix Pharmaceuticals Ltd FOMX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:FOMX)
www.bioportfolio.com - January 17 at 10:58 PM
finance.yahoo.com logoBlog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002 (NASDAQ:FOMX)
finance.yahoo.com - December 19 at 9:16 AM
insidermonkey.com logoIs Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds? (NASDAQ:FOMX)
www.insidermonkey.com - December 9 at 10:34 AM
News IconFoamix announces enrollment complete in trials of minocycline foam for acne (NASDAQ:FOMX)
www.healio.com - December 8 at 10:02 AM
us.rd.yahoo.com logoFoamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101 (NASDAQ:FOMX)
us.rd.yahoo.com - November 29 at 5:11 PM
us.rd.yahoo.com logoFoamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101 (NASDAQ:FOMX)
us.rd.yahoo.com - November 29 at 5:11 PM
us.rd.yahoo.com logo8:31 am Foamix has completed patient enrollment according to plan in the Company's two Phase 3 clinical trials to evaluate the efficacy and safety of FMX101; expects to report top-line results in the first half of 2017 (NASDAQ:FOMX)
us.rd.yahoo.com - November 29 at 5:11 PM
finance.yahoo.com logoFoamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea (NASDAQ:FOMX)
finance.yahoo.com - November 29 at 5:11 PM
capitalcube.com logoFoamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 (NASDAQ:FOMX)
www.capitalcube.com - November 23 at 4:57 PM
capitalcube.com logoFoamix Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : FOMX-US : November 18, 2016 (NASDAQ:FOMX)
www.capitalcube.com - November 18 at 8:49 AM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 16-Nov-16 1:30pm GMT (NASDAQ:FOMX)
finance.yahoo.com - November 17 at 8:06 AM
sg.finance.yahoo.com logoFoamix reports 3Q loss (NASDAQ:FOMX)
sg.finance.yahoo.com - November 15 at 5:35 PM
publicnow.com logoFoamix Reports Third Quarter 2016 Financial Results and Provides Business Update (NASDAQ:FOMX)
www.publicnow.com - November 15 at 5:35 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17 (NASDAQ:FOMX)
finance.yahoo.com - November 10 at 9:31 AM
publicnow.com logoFoamix Pharmaceuticals to Release Third Quarter 2016 Financial Results and Host Conference Call & Webcast on Wednesday, November 16 (NASDAQ:FOMX)
www.publicnow.com - November 7 at 8:24 AM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare Conference on November 7 (NASDAQ:FOMX)
finance.yahoo.com - November 3 at 8:12 AM
capitalcube.com logoFoamix Pharmaceuticals Ltd. breached its 50 day moving average in a Bearish Manner : FOMX-US : October 17, 2016 (NASDAQ:FOMX)
www.capitalcube.com - October 17 at 10:02 AM
News IconFoamix Pharmaceuticals Ltd. (FOMX) Stock: Great Point Partners Boosts its Stake to 7.57% (NASDAQ:FOMX)
feedproxy.google.com - October 12 at 6:14 AM
streetinsider.com logoFoamix (FOMX) Prices 6M Ordinary Shares Offering for Proceeds of ~$57M (NASDAQ:FOMX)
www.streetinsider.com - September 29 at 10:04 AM
publicnow.com logoFoamix Pharmaceuticals Ltd. Announces Pricing of its $57 Million Follow-on Offering of Ordinary Shares (NASDAQ:FOMX)
www.publicnow.com - September 28 at 9:56 AM
publicnow.com logoFoamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary Shares (NASDAQ:FOMX)
www.publicnow.com - September 27 at 5:02 PM
finance.yahoo.com logoCan The Uptrend Continue for Foamix Pharmaceuticals (FOMX)? (NASDAQ:FOMX)
finance.yahoo.com - September 21 at 9:19 AM
benzinga.com logoFoamix Announces Positive Topline Results from... (NASDAQ:FOMX)
www.benzinga.com - September 17 at 9:46 AM
finance.yahoo.com logoInside the Recent Surge in Biotech ETFs (NASDAQ:FOMX)
finance.yahoo.com - September 14 at 5:06 PM
News IconM&A Activity, Passing Drug Trials Help Biotech ETFs Rebound (NASDAQ:FOMX)
www.etftrends.com - September 12 at 4:54 PM
rttnews.com logoHere's Why You Need To Watch FOMX Today... (NASDAQ:FOMX)
www.rttnews.com - September 12 at 4:54 PM
finance.yahoo.com logoFoamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam … (NASDAQ:FOMX)
finance.yahoo.com - September 12 at 4:54 PM
schaeffersresearch.com logo2 Biotech Stocks Burning Short Sellers (NASDAQ:FOMX)
www.schaeffersresearch.com - September 12 at 4:54 PM
News IconFoamix Pharmaceuticals Ltd (NASDAQ:FOMX): Our Swing Trading Pick Rocked With 26% Profit In No Time (NASDAQ:FOMX)
www.marketnewscall.com - September 12 at 4:54 PM
marketwatch.com logoBiotech ETF gets a lift from Raptor deal, Foamix drug trial (NASDAQ:FOMX)
www.marketwatch.com - September 12 at 4:54 PM
finance.yahoo.com logo7:01 am Foamix topline results from phase 2 trial evaluating FMX-103 topical minocycline foam for moderate-to-severe papulopustular rosacea (NASDAQ:FOMX)
finance.yahoo.com - September 12 at 9:54 AM
publicnow.com logoFoamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea (NASDAQ:FOMX)
www.publicnow.com - September 12 at 9:54 AM
publicnow.com logoFoamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea (NASDAQ:FOMX)
www.publicnow.com - September 9 at 9:50 AM
finance.yahoo.com logoFoamix to Present Corporate Overview at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:FOMX)
finance.yahoo.com - September 6 at 9:51 AM
zacks.com logoHow Foamix (FOMX) Stock Stands Out in a Strong Industry (NASDAQ:FOMX)
www.zacks.com - August 29 at 9:42 AM
finance.yahoo.com logoWill Foamix Pharmaceuticals (FOMX) Continue to Surge Higher? (NASDAQ:FOMX)
finance.yahoo.com - August 16 at 5:11 PM
capitalcube.com logoFoamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:FOMX)
www.capitalcube.com - August 12 at 5:07 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 10-Aug-16 12:30pm GMT (NASDAQ:FOMX)
finance.yahoo.com - August 10 at 11:14 PM
schaeffersresearch.com logoAnalyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and Healthways, Inc. (NASDAQ:FOMX)
www.schaeffersresearch.com - August 10 at 5:17 PM
sg.finance.yahoo.com logoFoamix reports 2Q loss (NASDAQ:FOMX)
sg.finance.yahoo.com - August 10 at 12:30 PM
publicnow.com logoFoamix Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:FOMX)
www.publicnow.com - August 10 at 12:30 PM
publicnow.com logoFoamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, August 10 (NASDAQ:FOMX)
www.publicnow.com - July 25 at 8:18 AM
capitalcube.com logoETF’s with exposure to Foamix Pharmaceuticals Ltd. : June 24, 2016 (NASDAQ:FOMX)
www.capitalcube.com - June 24 at 5:32 PM
publicnow.com logoFoamix to Present at the BIO International Convention (NASDAQ:FOMX)
www.publicnow.com - June 1 at 8:23 AM
benzinga.com logoFoamix Pharmaceuticals Announces Publication of Abstract on FDX-104 for the 2016 ASCO Meeting - Benzinga (NASDAQ:FOMX)
www.benzinga.com - May 31 at 11:19 AM

Social

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

Where is Foamix Pharmaceuticals' stock going? Where will Foamix Pharmaceuticals' stock price be in 2017?

2 equities research analysts have issued 1 year target prices for Foamix Pharmaceuticals' stock. Their forecasts range from $20.00 to $22.00. On average, they expect Foamix Pharmaceuticals' stock price to reach $21.00 in the next year.

When will Foamix Pharmaceuticals announce their earnings?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Foamix Pharmaceuticals stock?

Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.21%), Menora Mivtachim Holdings LTD. (3.69%), Perceptive Advisors LLC (3.61%), Deerfield Management Co. (3.37%), Vivo Capital LLC (2.34%) and Alyeska Investment Group L.P. (1.79%).

Who sold Foamix Pharmaceuticals stock? Who is selling Foamix Pharmaceuticals stock?

Foamix Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Folger Hill Asset Management LP, Deerfield Management Co., Menta Capital LLC and Van ECK Associates Corp.

Who bought Foamix Pharmaceuticals stock? Who is buying Foamix Pharmaceuticals stock?

Foamix Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Trexquant Investment LP and Alyeska Investment Group L.P..

How do I buy Foamix Pharmaceuticals stock?

Shares of Foamix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Foamix Pharmaceuticals stock cost?

One share of Foamix Pharmaceuticals stock can currently be purchased for approximately $10.24.

Foamix Pharmaceuticals (NASDAQ:FOMX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Earnings History Chart

Earnings by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Dividend History Chart

Dividend Payments by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Last Updated on 2/19/2017 by MarketBeat.com Staff